Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa

a technology of fcgamma receptor and antibody composition, which is applied in the field of enhancing the binding activity of antibody composition to fcgamma receptor iiia, can solve the problems of complex structure of sugar chains and various sugar chains

Inactive Publication Date: 2004-12-23
KYOWA HAKKO KIRIN CO LTD
View PDF6 Cites 197 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, structures of sugar chains are various and complex actually, and it cannot be said that an important structure for the effector function was completely identified.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
  • Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
  • Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0727] Activity Evaluation of Anti-GD3 Chimeric Antibody:

[0728] 1. Binding Activity of Anti-GD3 Chimeric Antibody to GD3 (ELISA)

[0729] Binding activities of the five kinds of the purified anti-GD3 chimeric antibodies obtained in the item 4 of Example 1 to GD3 were measured by the ELISA shown in the item 3 of Example 1. FIG. 2 shows results of the examination of the binding activity measured by changing the concentration of the anti-GD3 chimeric antibody to be added. As shown in FIG. 2, the five kinds of the anti-GD3 chimeric antibodies showed almost the same binding activity to GD3. The result shows that antigen binding activities of these antibodies are constant independently of the antibody-producing animal cells and their culturing methods. Also, it was suggested from the comparison of the NS0-GD3 chimeric antibody (302) with the NS0-GD3 chimeric antibody (GIT) that the antigen binding activities are constant independently of the media used in the culturing.

[0730] 2. ADCC Activit...

example 3

[0739] Activity Evaluation of Anti-GD3 Chimeric Antibodies Having a Different Ratio of a Sugar Chain in which 1-Position of Fucose is not Bound to 6-Position of N-acetylglucosamine in the Reducing End:

[0740] 1. Preparation of Anti-GD3 Chimeric Antibodies Having a Different Ratio of a Sugar Chain in which 1-Position of Fucose is not Bound to 6-Position of N-acetylglucosamine in the Reducing End through .alpha.-Bond

[0741] In accordance with the method described in the item 2(1) of Example 1, some transformed clones derived from YB2 / 0 cell capable of producing an anti-GD3 chimeric antibody was obtained. Antibodies were prepared from the transformed clones derived from YB2 / 0 cell and named lot 1, lot 2 and lot 3. Sugar chain analysis of the anti-GD3 chimeric antibodies of lot 1, lot 2 and lot 3 was carried out by the following method.

[0742] The solution of ea ch purified antibody was exchanged to 10 mmol / L KH.sub.2PO.sub.4 using Ultra Free 0.5-10K (manufactured by Millipore). The exchan...

example 4

[0756] Activity Evaluation of Anti-CCR4 Chimeric Antibodies Having a Different Ratio of a Sugar Chain in which 1-Position of Fucose was not Bound to 6-Position of N-acetylglucosamine in the Reducing End through .alpha.-Bond.

[0757] 1. Preparation of Cells Stably Producing Anti-CCR4 Chimeric Antibody

[0758] Cells which are capable of stably producing an anti-CCR4 chimeric antibody were prepared as follows by using a tandem type expression vector pKANTEX2160 for an anti-CCR4 chimeric antibody described in WO01 / 64754.

[0759] (1) Preparation of Producing Cell Using Rat Myeloma YB2 / 0 Cell

[0760] After introducing 10 .mu.g of the anti-CCR4 chimeric antibody expression vector pKANTEX2160 into 4.times.10.sup.6 cells of rat myeloma YB2 / 0 cell (ATCC CRL 1662) by electroporation [Cytotechnology, 3, 133 (1990)], the cells were suspended in 40 ml of Hybridoma-SFM-FBS(5) [Hybridoma-SFM medium (manufactured by Invitrogen) comprising 5% FBS (manufactured by PAA Laboratories)] and dispensed at 200 .mu.l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
binding constantaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

A method for enhancing a binding activity of an antibody composition to Fcgamma receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcgamma receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.

Description

BACKGROUND OF TE INVENTION[0001] 1. Field of the Invention[0002] The present invention relates to a method for enhancing a binding activity of an antibody composition to Fc.gamma. receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fc.gamma. receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P9/00A61P29/00A61P31/04A61P31/12A61P31/14A61P35/00A61P37/02A61P37/04A61P37/08A61P43/00C07K16/22C07K16/28C07K16/30C12P21/02C12P21/08
CPCA61K39/395C07K16/22C07K16/283C07K16/2866C07K16/3084C07K2317/24C07K2317/41C07K2317/732C07K2319/30C12P21/02A61P9/00A61P29/00A61P31/04A61P31/12A61P31/14A61P35/00A61P37/02A61P37/04A61P37/08A61P43/00
Inventor NAKAMURA, KAZUYASUSHITARA, KENYA
Owner KYOWA HAKKO KIRIN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap